Burden Among Caregivers of Pediatric Patients with Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibroma (PN) in the United States: A Cross-Sectional Study

被引:7
|
作者
Yang, Xiaoqin [1 ]
Yoo, Hyun Kyoo [2 ]
Amin, Suvina [3 ]
Cheng, Wendy Y. [4 ]
Sundaresan, Sanjana [4 ]
Zhang, Lujia [4 ]
Duh, Mei S. [4 ]
机构
[1] Merck & Co Inc, Rahway, NJ 07065 USA
[2] AstraZeneca Rare Dis, Alex, Cambridge, England
[3] AstraZeneca, Gaithersburg, MD USA
[4] Anal Grp Inc, Boston, MA USA
关键词
Neurofibromatosis type 1; Plexiform neurofibromas; Caregiver burden; Work productivity loss; Activity impairment; Cross-sectional study; Zarit Burden Interview; WPAI; Quality of life; CHILDREN; DISEASE; ADOLESCENTS; MORBIDITY; DISTRESS; FAMILIES; PARENTS; YOUTH;
D O I
10.1007/s40120-022-00365-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Patients with neurofibromatosis type 1 (NF1) may develop plexiform neurofibromas (PNs) that can cause disfigurement, pain, and dysfunction, and may even be life-threatening. Studies have indicated NF1-PN can substantially impact the quality of life (QoL) of pediatric patients. However, research on caregiver burden is scarce. Methods Caregivers of pediatric patients ages 2-18 years with NF1-PN in the USA were recruited through the Children's Tumor Foundation to participate in an online cross-sectional survey (December 2020-January 2021). Caregiver burden was measured using the Zarit Burden Interview (ZBI), and productivity loss from patientcare was measured using the Work Productivity and Activity Impairment questionnaire, adapted for caregiving (WPAI:CG). Results Ninety-five caregivers were recruited with a median age of 44.0 years. Most were female (88.4%), white/Caucasian (85.3%), and did not have NF1 or PN (86.3% and 89.5%, respectively). Commonly reported health conditions among caregivers include anxiety (48.4%) and depression (34.7%). On the ZBI (range 0-88; higher = greater burden), mean (SD) scores were 23.0 (13.8) and 12.7% of caregivers reported moderate-severe (scores 41-60) or severe burden (scores 61-88). Fifty-six caregivers were employed and working in the 7 days prior to completing the WPAI:CG. They reported missing an average of 6.9% of their working hours and an average reduction of 17.3% of on-the-job effectiveness, contributing to 22.3% loss in work productivity. Among all 95 caregivers, an average of 17.2% of regular daily activities were impaired. Conclusions The burden among caregivers of pediatric patients with NF1-PN is considerable and underscores an unmet need for better disease management.
引用
收藏
页码:1221 / 1233
页数:13
相关论文
共 50 条
  • [1] Burden Among Caregivers of Pediatric Patients with Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibroma (PN) in the United States: A Cross-Sectional Study
    Xiaoqin Yang
    Hyun Kyoo Yoo
    Suvina Amin
    Wendy Y. Cheng
    Sanjana Sundaresan
    Lujia Zhang
    Mei S. Duh
    Neurology and Therapy, 2022, 11 : 1221 - 1233
  • [2] CLINICAL BURDEN AMONG PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND PLEXIFORM NEUROFIBROMA (PN) IN THE UNITED STATES (US)
    Yang, Xiaoqin
    Yoo, Hyun Kyoo
    Amin, Suvina
    Cheng, Wendy
    Sipsma, Heather
    Sundaresan, Sanjana
    Zhang, Lujia
    Duh, Mei Sheng
    NEURO-ONCOLOGY, 2021, 23 : 41 - 42
  • [3] HEALTH-RELATED QUALITY OF LIFE (HRQOL) AMONG PEDIATRIC PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND PLEXIFORM NEUROFIBROMA (PN) IN THE UNITED STATES: PERSPECTIVES OF THE PATIENTS AND CAREGIVERS
    Yang, Xiaoqin
    Yoo, Hyun Kyoo
    Amin, Suvina
    Cheng, Wendy
    Sipsma, Heather
    Sundaresan, Sanjana
    Zhang, Lujia
    Duh, Mei Sheng
    NEURO-ONCOLOGY, 2021, 23 : 182 - 183
  • [4] Health-related quality of life (HRQoL) among pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) in the United States (US).
    Yang, Xiaoqin
    Yoo, Hyun Kyoo
    Amin, Suvina
    Cheng, Wendy Y.
    Sipsma, Heather
    Sundaresan, Sanjana
    Zhang, Lujia
    Duh, Mei Sheng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] PREDICTORS OF PLEXIFORM NEUROFIBROMA (PN) GROWTH IN PATIENTS WITH NEUROFIBROMATOSIS 1 (NF1)
    Akshintala, Srivandana
    Dombi, Eva
    Baldwin, Andrea
    Gillespie, Andy
    Goodspeed, Wendy
    Goodwin, Anne
    Whitcomb, Patricia
    Steinberg, Seth
    Widemann, Brigitte
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S32 - S33
  • [6] Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA
    Xiaoqin Yang
    Hyun Kyoo Yoo
    Suvina Amin
    Wendy Y. Cheng
    Sanjana Sundaresan
    Lujia Zhang
    Mei Sheng Duh
    Child's Nervous System, 2022, 38 : 1513 - 1522
  • [7] Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA
    Yang, Xiaoqin
    Yoo, Hyun Kyoo
    Amin, Suvina
    Cheng, Wendy Y.
    Sundaresan, Sanjana
    Zhang, Lujia
    Duh, Mei Sheng
    CHILDS NERVOUS SYSTEM, 2022, 38 (08) : 1513 - 1522
  • [8] A phase I study of thalidomide for the treatment of plexiform neurofibroma in patients with neurofibromatosis 1 (NF1)
    Gupta, A
    Cohen, BH
    Ruggieri, P
    Packer, RJ
    Phillips, P
    NEUROLOGY, 2000, 54 (07) : A12 - A13
  • [9] Radiosurgical treatment of ulnar plexiform neurofibroma in a neurofibromatosis type 1 (NF1) patient
    Marchetti, Marcello
    Franzini, Angelo
    Nazzi, Vittoria
    De Martin, Elena
    Fariselli, Laura
    ACTA NEUROCHIRURGICA, 2013, 155 (03) : 553 - 555
  • [10] Radiosurgical treatment of ulnar plexiform neurofibroma in a neurofibromatosis type 1 (NF1) patient
    Marcello Marchetti
    Angelo Franzini
    Vittoria Nazzi
    Elena De Martin
    Laura Fariselli
    Acta Neurochirurgica, 2013, 155 : 553 - 555